BHV3000-302 : Phase 3: Double-Blind, Randomized, Placebo-Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) for the Acute Treatment of Migraine

Trial Profile

BHV3000-302 : Phase 3: Double-Blind, Randomized, Placebo-Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) for the Acute Treatment of Migraine

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Jun 2018

At a glance

  • Drugs Rimegepant (Primary)
  • Indications Migraine
  • Focus Registrational; Therapeutic Use
  • Sponsors Biohaven Pharmaceutical Holding Company
  • Most Recent Events

    • 28 Jun 2018 According to a Biohaven Pharmaceutical Holding Company media release, data from this trial will be presented at the the American Headache Society (AHS) Annual Scientific Meeting 2018.
    • 05 Jun 2018 According to a Biohaven Pharmaceutical Holding Company media release, expanded data will be presented at the American Headache Society (AHS) 60th Annual Scientific Meeting 2018.
    • 22 Apr 2018 According to a Biohaven Pharmaceutical Holding Company media release, data from this study were webcast at an Investor event : The American Academy of Neurology meeting
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top